Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Chen, Christine"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 40
Tytuł:
Daily Rapid Antigen Exit Testing to Tailor University COVID-19 Isolation Policy.
Autorzy:
Earnest R
Chen C
Chaguza C
Hahn AM
Grubaugh ND
Wilson MS
Pokaż więcej
Corporate Authors:
Yale COVID-19 Resulting and Isolation Team
Źródło:
Emerging infectious diseases [Emerg Infect Dis] 2022 Dec; Vol. 28 (12), pp. 2455-2462.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*
Vaccines*
Humans ; Universities ; Policy ; Students
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Autorzy:
Kaedbey R; Department of Hematology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Forward N; Department of Medicine, Dalhousie University/Nova Scotia Health, Halifax, NS B3H 2Y9, Canada.
Sehn LH; Department of Medical Oncology, BC Cancer Centre for Lymphoid Cancer, Vancouver, BC V5Z 4E6, Canada.
Shafey M; Department of Medicine, Division of Hematology, Foothills Medical Centre and University of Calgary, Calgary, AB T2N 2T9, Canada.
Doucette S; Impact Medicom Inc., Toronto, ON M6S 3K2, Canada.
Chen CI; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Suite 6-225, Toronto, ON M5G 2M9, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Sep 28; Vol. 29 (10), pp. 7122-7139. Date of Electronic Publication: 2022 Sep 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Waldenstrom Macroglobulinemia*/drug therapy
Waldenstrom Macroglobulinemia*/diagnosis
Hematopoietic Stem Cell Transplantation*
Humans ; Rituximab/therapeutic use ; Bendamustine Hydrochloride/therapeutic use ; Agammaglobulinaemia Tyrosine Kinase ; Proteasome Inhibitors/therapeutic use ; Quality of Life ; Transplantation, Autologous ; Canada ; Immunoglobulin M/therapeutic use ; Purines/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combat and Operational Stress Control Interventions and PTSD: A Systematic Review and Meta-Analysis.
Autorzy:
Maglione MA; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, RAND Corporation, Santa Monica, CA 90407, USA.
Chen C; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, RAND Corporation, Santa Monica, CA 90407, USA.
Bialas A; RAND Corporation, Pittsburgh, PA 15213, USA.
Motala A; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, RAND Corporation, Santa Monica, CA 90407, USA.; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, USA.
Chang J; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, RAND Corporation, Santa Monica, CA 90407, USA.
Akinniranye O; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, RAND Corporation, Santa Monica, CA 90407, USA.
Hempel S; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, RAND Corporation, Santa Monica, CA 90407, USA.; The Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, USA.
Pokaż więcej
Źródło:
Military medicine [Mil Med] 2022 Jul 01; Vol. 187 (7-8), pp. e846-e855.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Cognitive Behavioral Therapy*
Eye Movement Desensitization Reprocessing*
Stress Disorders, Post-Traumatic*/prevention & control
Stress Disorders, Post-Traumatic*/psychology
Counseling ; Humans ; Psychotherapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Author Correction: Neuroimaging and cognitive correlates of retinal Optical Coherence Tomography (OCT) measures at late middle age in a twin sample.
Autorzy:
Moran C; National Centre for Healthy Ageing, Melbourne, Australia.; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia.; Department of Aged Care, Alfred Health, Melbourne, Australia.
Xu ZY; Royal Free London NHS Foundation Trust, London, UK.; UCL Medical School, London, UK.
Mehta H; Royal Free London NHS Foundation Trust, London, UK.; Macular Research Group, University of Sydney, Sydney, Australia.
Gillies M; Macular Research Group, University of Sydney, Sydney, Australia.
Karayiannis C; National Centre for Healthy Ageing, Melbourne, Australia.; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia.
Beare R; National Centre for Healthy Ageing, Melbourne, Australia.; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia.
Chen C; Department of Ophthalmology, Monash Health, Melbourne, Australia.
Srikanth V; National Centre for Healthy Ageing, Melbourne, Australia. .; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 27; Vol. 12 (1), pp. 10860. Date of Electronic Publication: 2022 Jun 27.
Typ publikacji:
Published Erratum
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neuroimaging and cognitive correlates of retinal Optical Coherence Tomography (OCT) measures at late middle age in a twin sample.
Autorzy:
Moran C; National Centre for Healthy Ageing, Melbourne, Australia.; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia.; Department of Aged Care, Alfred Health, Melbourne, Australia.
Xu ZY; Royal Free London NHS Foundation Trust, London, UK.; UCL Medical School, London, UK.
Mehta H; Royal Free London NHS Foundation Trust, London, UK.; Macular Research Group, University of Sydney, Sydney, Australia.
Gillies M; Macular Research Group, University of Sydney, Sydney, Australia.
Karayiannis C; National Centre for Healthy Ageing, Melbourne, Australia.; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia.
Beare R; National Centre for Healthy Ageing, Melbourne, Australia.; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia.
Chen C; Department of Ophthalmology, Monash Health, Melbourne, Australia.
Srikanth V; National Centre for Healthy Ageing, Melbourne, Australia. .; Department of Geriatric Medicine, Peninsula Health and Central Clinical School, Monash University, Melbourne, Australia. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 10; Vol. 12 (1), pp. 9562. Date of Electronic Publication: 2022 Jun 10.
Typ publikacji:
Journal Article; Twin Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetes Mellitus, Type 2*
Tomography, Optical Coherence*/methods
Cognition ; Diffusion Tensor Imaging ; Female ; Humans ; Male ; Middle Aged ; Neuroimaging ; Retina/diagnostic imaging
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease.
Autorzy:
Yazar S; Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Alquicira-Hernandez J; Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.; Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
Wing K; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.; Department of Ophthalmology, Royal Hobart Hospital, Hobart, TAS, Australia.
Senabouth A; Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Gordon MG; Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.; Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
Andersen S; Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
Lu Q; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Rowson A; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.; Department of Surgery, School of Clinical Science at Monash Health, Monash University, VIC, Australia.
Taylor TRP; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Clarke L; Centre for Eye Research Australia, University of Melbourne, East Melbourne, VIC, Australia.
Maccora K; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.; Department of Surgery, School of Clinical Science at Monash Health, Monash University, VIC, Australia.
Chen C; Department of Surgery, School of Clinical Science at Monash Health, Monash University, VIC, Australia.
Cook AL; Wicking Dementia Research and Education Centre, University of Tasmania, Hobart, TAS, Australia.
Ye CJ; Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.; Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.; Institute of Computational Health Sciences, University of California, San Francisco, San Francisco, CA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.; Chan Zuckerberg Biohub, San Francisco, CA, USA.
Fairfax KA; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Hewitt AW; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.; Department of Ophthalmology, Royal Hobart Hospital, Hobart, TAS, Australia.; Centre for Eye Research Australia, University of Melbourne, East Melbourne, VIC, Australia.
Powell JE; Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.; UNSW Cellular Genomics Futures Institute, University of New South Wales, Sydney, NSW, Australia.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Apr 08; Vol. 376 (6589), pp. eabf3041. Date of Electronic Publication: 2022 Apr 08.
Typ publikacji:
Journal Article
MeSH Terms:
Autoimmune Diseases*/genetics
Leukocytes, Mononuclear*
Alleles ; Gene Expression Regulation ; Genetic Predisposition to Disease ; Genome-Wide Association Study ; Humans ; Polymorphism, Single Nucleotide ; Precursor Cells, B-Lymphoid ; Quantitative Trait Loci ; Sequence Analysis, RNA
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of patient characteristics on posttraumatic stress disorder treatment retention among veterans: A systematic review.
Autorzy:
Maglione MA; RAND Corporation, Santa Monica, California, USA.; Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Chen C; RAND Corporation, Santa Monica, California, USA.
Franco M; RAND Corporation, Santa Monica, California, USA.
Gizaw M; RAND Corporation, Santa Monica, California, USA.
Shahidinia N; RAND Corporation, Santa Monica, California, USA.
Baxi S; RAND Corporation, Santa Monica, California, USA.
Hempel S; Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Pokaż więcej
Źródło:
Journal of traumatic stress [J Trauma Stress] 2022 Apr; Vol. 35 (2), pp. 718-728. Date of Electronic Publication: 2021 Nov 20.
Typ publikacji:
Journal Article; Systematic Review; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Military Personnel*
Stress Disorders, Post-Traumatic*/complications
Stress Disorders, Post-Traumatic*/epidemiology
Stress Disorders, Post-Traumatic*/therapy
Veterans*
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
Autorzy:
Rivera Duarte A; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Reece D; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Li X; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
Xu W; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
Paul H; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Masih-Khan E; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Winter A; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Tiedemann R; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Prica A; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Chen C; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Trudel S; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Kukreti V; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Pokaż więcej
Źródło:
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis [Amyloid] 2022 Mar; Vol. 29 (1), pp. 23-30. Date of Electronic Publication: 2021 Sep 14.
Typ publikacji:
Journal Article
MeSH Terms:
Amyloidosis*/drug therapy
Immunoglobulin Light-chain Amyloidosis*/drug therapy
Multiple Myeloma*
Humans ; Middle Aged ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains.
Autorzy:
Lebel E; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Li X; Biostatistics Research Unit, University Health Network, Toronto, Ontario, Canada.
Paul H; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Masih-Khan E; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Bhella S; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Chen C; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Prica A; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Reece D; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Tiedemann R; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Trudel S; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Kukreti V; Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2022 Mar; Vol. 108 (3), pp. 204-211. Date of Electronic Publication: 2021 Nov 19.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/therapeutic use ; Dexamethasone ; Humans ; Kinetics ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study.
Autorzy:
Mayo SJ; Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, 155 College St., Suite 130, Toronto, ON, M5T 1P8, Canada. .; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .
Rourke SB; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Atenafu EG; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Vitorino R; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Chen C; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medicine, University of Toronto, Toronto, ON, Canada.
Kuruvilla J; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medicine, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło:
Pilot and feasibility studies [Pilot Feasibility Stud] 2021 Jan 30; Vol. 7 (1), pp. 36. Date of Electronic Publication: 2021 Jan 30.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Autorzy:
Belch A; Cross Cancer Institute, Edmonton, AB, Canada.
Bahlis N; Tom Baker Cancer Centre, Calgary, AB, Canada.
White D; Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
Cheung M; Odette Cancer Centre, Toronto, ON, Canada.
Chen C; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Shustik C; McGill University Health Centre, Montréal, QC, Canada.
Song K; Leukemia/Bone Marrow Transplant Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada.
Tosikyan A; Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada.
Dispenzieri A; Mayo Clinic, Rochester, MN, USA.
Anderson K; Dana-Farber Cancer Institute, Boston, MA, USA.
Brown D; Celgene, a Bristol-Myers Squibb Company, Mississauga, ON, Canada.
Robinson S; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Srinivasan S; Bristol Myers Squibb, Princeton, NJ, USA.
Facon T; Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Dec; Vol. 9 (23), pp. 8923-8930. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji:
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Dexamethasone/*administration & dosage
Lenalidomide/*administration & dosage
Multiple Myeloma/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Canada ; Dexamethasone/adverse effects ; Disease Progression ; Drug Administration Schedule ; Eligibility Determination ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Lenalidomide/adverse effects ; Male ; Melphalan/administration & dosage ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Prednisone/administration & dosage ; Progression-Free Survival ; Thalidomide/administration & dosage ; Time Factors ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Syngeneic transplants for multiple myeloma - a single center experience and review of the literature.
Autorzy:
Lebel E; Princess Margaret Cancer Centre, Toronto, Canada.
Prica A; Princess Margaret Cancer Centre, Toronto, Canada.
Bhella S; Princess Margaret Cancer Centre, Toronto, Canada.
Kukreti V; Princess Margaret Cancer Centre, Toronto, Canada.
Tiedemann R; Princess Margaret Cancer Centre, Toronto, Canada.
Trudel S; Princess Margaret Cancer Centre, Toronto, Canada.
Reece D; Princess Margaret Cancer Centre, Toronto, Canada.
Chen C; Princess Margaret Cancer Centre, Toronto, Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (14), pp. 3519-3522. Date of Electronic Publication: 2020 Sep 14.
Typ publikacji:
Letter; Review
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/therapy
Humans ; Isografts ; Transplantation, Autologous ; Transplantation, Isogeneic
Recenzja
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparing covariation among vaccine hesitancy and broader beliefs within Twitter and survey data.
Autorzy:
Nowak SA; Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States of America.; RAND Corporation, Boston, Massachusetts, United States of America.
Chen C; Pardee RAND Graduate School, Santa Monica, California, United States of America.
Parker AM; RAND Corporation, Pittsburgh, Pennsylvania, United States of America.
Gidengil CA; RAND Corporation, Boston, Massachusetts, United States of America.; Boston Children's Hospital, Boston, Massachusetts, United States of America.
Matthews LJ; RAND Corporation, Boston, Massachusetts, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2020 Oct 08; Vol. 15 (10), pp. e0239826. Date of Electronic Publication: 2020 Oct 08 (Print Publication: 2020).
Typ publikacji:
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Public Opinion*
Social Media/*statistics & numerical data
Vaccination Refusal/*statistics & numerical data
Communication ; Humans ; Surveys and Questionnaires ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
Autorzy:
Chen CI; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Cao Y; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Trudel S; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Reece DE; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Kukreti V; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Tiedemann R; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Prica A; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Paul H; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Le LW; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
Levina O; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Kakar S; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Lau A; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
Chen H; QPS, LLC, Newark, NJ, USA.
Chen E; Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Aug; Vol. 61 (8), pp. 1860-1868. Date of Electronic Publication: 2020 May 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/complications
Multiple Myeloma*/drug therapy
Renal Insufficiency*/complications
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/therapeutic use ; Humans ; Lenalidomide/therapeutic use ; Thalidomide/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An algorithm competition for automatic species identification from herbarium specimens.
Autorzy:
Little DP; The New York Botanical Garden 2900 Southern Boulevard Bronx New York 10458 USA.
Tulig M; The New York Botanical Garden 2900 Southern Boulevard Bronx New York 10458 USA.
Tan KC; Google Research 111 8th Avenue New York New York 10011 USA.
Liu Y; Google Research 111 8th Avenue New York New York 10011 USA.; Present address: Snapchat NYC 229 W. 43rd Street New York New York 10036 USA.
Belongie S; Google Research 111 8th Avenue New York New York 10011 USA.; Cornell Tech 2 W. Loop Rd. New York New York 10044 USA.
Kaeser-Chen C; Google Research 111 8th Avenue New York New York 10011 USA.
Michelangeli FA; The New York Botanical Garden 2900 Southern Boulevard Bronx New York 10458 USA.
Panesar K; Google Inc. 1600 Amphitheatre Parkway Mountain View California 94043 USA.
Guha RV; Google Inc. 1600 Amphitheatre Parkway Mountain View California 94043 USA.
Ambrose BA; The New York Botanical Garden 2900 Southern Boulevard Bronx New York 10458 USA.
Pokaż więcej
Źródło:
Applications in plant sciences [Appl Plant Sci] 2020 Jul 01; Vol. 8 (6), pp. e11365. Date of Electronic Publication: 2020 Jul 01 (Print Publication: 2020).
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.
Autorzy:
Vijenthira A; Postgraduate Medical Education, University of Toronto , Toronto , Canada.
Maganti M; Department of Biostatistics, Princess Margaret Cancer Centre , Toronto , Canada.
Kukreti V; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada.
Kuruvilla J; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada.
Tiedemann R; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada.
Chen C; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada.
Crump M; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada.
Prica A; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Oct; Vol. 60 (10), pp. 2576-2579. Date of Electronic Publication: 2019 Apr 18.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Immunological/*therapeutic use
Lymphoma/*drug therapy
Lymphoma/*pathology
Rituximab/*therapeutic use
Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Humans ; Molecular Targeted Therapy ; Prognosis ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Treatment Outcome
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
Autorzy:
Chen CI; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Paul H; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Snitzler S; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Kakar S; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Le LW; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Wei EN; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Lau A; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Johnston JB; b Manitoba Institute of Cell Biology , Winnipeg , ( MN ), Canada.
Gibson SB; b Manitoba Institute of Cell Biology , Winnipeg , ( MN ), Canada.
Queau M; b Manitoba Institute of Cell Biology , Winnipeg , ( MN ), Canada.
Spaner D; c Sunnybrook Health Sciences Centre , Toronto , ( ON ), Canada.
Croucher D; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Sherry B; d Karches Center for Oncology Research , The Feinstein Institute for Medical Research , Manhasset , ( NY ) USA.
Trudel S; a Princess Margaret Cancer Centre , Toronto , ( ON ) Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Apr; Vol. 60 (4), pp. 980-989. Date of Electronic Publication: 2018 Oct 02.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers ; Cytokines/metabolism ; Dexamethasone/administration & dosage ; Female ; Humans ; Kaplan-Meier Estimate ; Lenalidomide/administration & dosage ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A phase 2 study of ofatumumab (Arzerra ) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).
Autorzy:
Chen CI; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Paul H; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Le LW; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Wei EN; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Snitzler S; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Wang T; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Levina O; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Kakar S; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Lau A; b Department of Biostatistics , Princess Margaret Cancer Centre , Toronto , ON , Canada.
Queau M; c Manitoba Institute of Cell Biology , Winnipeg , MB , Canada.
Johnston JB; c Manitoba Institute of Cell Biology , Winnipeg , MB , Canada.
Smith DA; d Clin Pharm Advantage LLC , Durham , NC , USA.
Trudel S; a Princess Margaret Cancer Centre/Ontario Cancer Institute , Toronto , ON , Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Jan; Vol. 60 (1), pp. 92-100. Date of Electronic Publication: 2018 Jun 19.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Neutropenia/*epidemiology
Pyrazoles/*administration & dosage
Thiophenes/*administration & dosage
Administration, Oral ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Neutropenia/chemically induced ; Progression-Free Survival ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Pyrazoles/adverse effects ; Remission Induction/methods ; Thiophenes/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bilateral posterior capsule injury after Nd:YAG laser vitreolysis: unintended consequence of floaters treatment.
Autorzy:
O'Day R; Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.; Department of Surgery, Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
Cugley D; Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Chen C; Department of Surgery, Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
Fabinyi D; Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Pokaż więcej
Źródło:
Clinical & experimental ophthalmology [Clin Exp Ophthalmol] 2018 Nov; Vol. 46 (8), pp. 956-958. Date of Electronic Publication: 2018 Apr 06.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Postoperative Complications*
Eye Diseases/*surgery
Laser Therapy/*adverse effects
Lasers, Solid-State/*adverse effects
Posterior Capsule of the Lens/*injuries
Vitreous Body/*surgery
Eye Diseases/diagnosis ; Female ; Humans ; Middle Aged ; Posterior Capsule of the Lens/diagnostic imaging ; Posterior Capsule of the Lens/surgery ; Reoperation ; Rupture
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Economic benefits of microprocessor controlled prosthetic knees: a modeling study.
Autorzy:
Chen C; RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.
Hanson M; RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.
Chaturvedi R; RAND Corporation, 1200 South Hayes Street, Arlington, VA, 22202-5050, USA.
Mattke S; RAND Corporation, 20 Park Plaza, Suite 920, Boston, MA, 02116, USA.
Hillestad R; RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.
Liu HH; RAND Corporation, 20 Park Plaza, Suite 920, Boston, MA, 02116, USA. .
Pokaż więcej
Źródło:
Journal of neuroengineering and rehabilitation [J Neuroeng Rehabil] 2018 Sep 05; Vol. 15 (Suppl 1), pp. 62. Date of Electronic Publication: 2018 Sep 05.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Prosthesis Design*
Knee Prosthesis/*economics
Microcomputers/*economics
Robotics/*economics
Robotics/*methods
Accidental Falls/statistics & numerical data ; Amputees ; Cost-Benefit Analysis ; Humans ; Medicare ; Quality of Life ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 40

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies